Owens & Minor swings to huge Q2 GAAP loss as P&HS held-for-sale, $80M Rotech break fee

Owens & Minor, Inc. (NYSE: OMI) - Quick take: the company is executing a major portfolio reshuffle. Management has classified the Products & Healthcare Services (P&HS) segment as held-for-sale (discontinued operations), terminated the Rotech acquisition (paid an $80,000,000 breakage fee) and recorded large one‑time non‑cash charges that drove a massive GAAP loss this quarter despite continued operating strength in the remaining business.

What's happening inside the company
- The P&HS segment is in active sale discussions and is classified as discontinued operations and assets held for sale as of June 30, 2025.
- Classification of P&HS as held-for-sale resulted in a valuation allowance / loss on classification to held-for-sale of $649,140 (six months ended June 30, 2025) and a goodwill impairment of $106,389 attributable to P&HS.
- The planned acquisition of Rotech was mutually terminated on June 3, 2025; Owens & Minor paid a transaction breakage fee of $80,000 during Q2 and recognized $18,288 in transaction financing fees.
- Management is pursuing a smaller, focused operating company (Patient Direct) after the contemplated divestiture; they also authorized a $100 million share repurchase program (up to 24 months) and repurchased ~0.8M shares YTD for $6.6M.

Key income-statement and balance-sheet facts (as reported)
- Net revenue (Q2 2025): $681,917 (Q2 2024: $660,401) - +3.3%.
- Net revenue (6 months 2025): $1,355,801 (6M 2024: $1,298,244) - +4.4%.
- Cost of net revenue (Q2 2025): $357,315; gross margins compressed modestly but roughly in line with revenue growth.
- SG&A (Q2 2025): $267,853 (down slightly from $269,919). SG&A as % of revenue: 39.3% (Q2).
- Transaction breakage fee: $80,000 (recognized in Q2 2025).
- Acquisition-related charges & intangible amortization (Q2 2025): $13,918.
- Operating (loss) income (Q2 2025): $(39,710) (Q2 2024: $16,922).
- Loss from continuing operations, net of tax (Q2 2025): $(83,822) (Q2 2024: $(6,742)).
- Loss from discontinued operations, net of tax (Q2 2025): $(785,236) (Q2 2024: $(25,171)).
- Net loss (Q2 2025): $(869,058) vs. $(31,913) prior year quarter. Basic loss per share (Q2 2025): $(11.30).
- Adjusted EBITDA (non‑GAAP): Q2 2025 = $96,635; 6M 2025 = $192,653 (management's core operating profitability measure).
- Cash & cash equivalents (continuing ops line): $38,258 (Total cash including discontinued ops in statement of cash flows: $77,087 at June 30, 2025).
- Total debt (carrying amount): $1,977,745; long-term debt (ex‑current portion): $1,594,745. Current maturities included $383,000 expected to be repaid within 12 months in connection with expected P&HS sale proceeds.
- Total assets: $4,154,545; total liabilities: $4,435,555. Total (deficit) equity: $(281,010) (June 30, 2025).

Positive aspects of the income statement / underlying business
- Revenue growth: organic growth across several product categories - sleep therapy, ostomy, urology - produced a 3.3% Q2 and 4.4% YTD increase in net revenue.
- Adjusted EBITDA of $96.6M (Q2) and $192.7M (6M) indicates the continuing operations generate meaningful cash profits after excluding one‑time and non‑operating items.
- SG&A improved slightly in absolute dollars and as a percent of revenue (operational efficiencies noted in revenue cycle and IT).
- Strong working-capital actions: receivables sale program provided substantial cash proceeds (Receivables Sale Program: $496M sold in Q2 and $840M YTD, with ~$160M of uncollected sold A/R shown as intercompany receivable tied to discontinued ops).
- Management is taking decisive portfolio actions (divestiture, cost realignment) to sharpen strategic focus.

Negative aspects of the income statement / financial position
- Massive one‑time charges tied to P&HS classification: $649,140 loss on classification to held-for-sale and $106,389 goodwill impairment drove the huge discontinued-operations loss (Q2 discontinued loss = $(785,236)). These are non‑cash but severely damage GAAP earnings and equity.
- Continuing operations still loss-making on GAAP this quarter: loss from continuing ops $(83,822) in Q2 (impacted by the $80M breakage fee, $18.3M financing fees, and higher acquisition-related costs).
- Net loss and equity deficit: consolidated net loss for Q2 $(869,058) and total equity deficit $(281,010) - balance-sheet leverage and deficit equity raise investor concern until P&HS sale closes and proceeds are applied.
- High gross debt load: nearly $2.0B total debt with substantial near-term maturities (current maturities $383M) - sale proceeds will be key to de‑leveraging; cross‑default provisions remain a potential governance risk.
- Revenue concentration & payor risk: two largest commercial payors represented ~24% and 14% of net revenue (6M 2025) and the company disclosed a termination notice from a commercial payor representing ~$160M (12% of net revenue for 6M) - execution risk to retain or replace that revenue.
- Regulatory / reimbursement risk: CMS final NCD for NIPPV (June 2025) could reduce qualification for non‑invasive ventilation and negatively affect home respiratory revenue mix.
- One‑time financing and breakage costs (Rotech): $80M breakage fee + $18.3M transaction financing fees hit both cash and reported earnings in the quarter.

Operational & liquidity notes investors should watch
- Progress and terms of the P&HS sale (timing, proceeds, post‑closing liabilities and transitional services fees) - proceeds expected to be used to repay near‑term debt.
- Covenant compliance and refinancing risk if the sale is delayed; revolving availability was $286M at June 30, 2025 (after $135M borrowings and $29M letters of credit).
- Trends in core Patient Direct revenue and Adjusted EBITDA (proof that continuing operations can sustain liquidity and creditor obligations without P&HS).
- Resolution of payor contract termination and whether replacement business or cost reductions offset the ~$160M revenue exposure.
- Any further impairment or valuation charges related to assets held for sale or other segments.

Bottom line: Owens & Minor (NYSE: OMI) is in transformation. The headline GAAP numbers for Q2 are heavily distorted by strategic one‑time items (held‑for‑sale write‑downs, goodwill impairment, Rotech breakage and financing fees). Under the surface, continuing operations show revenue growth and positive Adjusted EBITDA, but high leverage, a large equity deficit and near‑term debt maturities make the timing and size of the P&HS sale-and management's ability to execute payor / cost actions-critical for restoring balance‑sheet health and investor confidence.

If you want: I can (1) prepare a concise slide with the top 8 metrics and risks, (2) model pro‑forma debt after several sale scenarios, or (3) draft a short investor Q&A you could use to test management answers on timing and use of proceeds.